Cencora (NYSE:COR) Given New $380.00 Price Target at Argus

Posted by Stanley Muller on Oct 20th, 2026

Cencora (NYSE:COR – Get Free Report) had its price target hoisted by equities researchers at Argus from $340.00 to $380.00 in a report released on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Argus’ target price points to a potential upside of 11.74% from the company’s current price.

Several other analysts have also recently weighed in on COR. Leerink Partners raised their price objective on shares of Cencora from $380.00 to $388.00 and gave the company an “outperform” rating in a research report on Wednesday, October 7th. Wells Fargo & Company upped their target price on shares of Cencora from $331.00 to $395.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 11th. Weiss Ratings upgraded shares of Cencora from a “buy (b-)” rating to a “buy (b)” rating in a research report on Tuesday, October 6th. Citigroup reissued a “buy” rating on shares of Cencora in a research note on Thursday, August 6th. Finally, Bank of America raised their price target on Cencora from $285.00 to $310.00 in a research report on Tuesday, July 21st. Fourteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $366.31.

Read Our Latest Research Report on Cencora

Cencora Stock Down 0.2%

COR stock opened at $340.07 on Tuesday. The company has a current ratio of 0.93, a quick ratio of 0.58 and a debt-to-equity ratio of 3.53. The company’s 50 day moving average is $320.70 and its 200 day moving average is $303.48. The stock has a market cap of $64.90 billion, a price-to-earnings ratio of 25.27, a price-to-earnings-growth ratio of 1.75 and a beta of 0.58. Cencora has a 1-year low of $244.82 and a 1-year high of $377.54.

Cencora (NYSE:COR – Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $4.48 earnings per share for the quarter, beating analysts’ consensus estimates of $4.35 by $0.13. Cencora had a net margin of 0.79% and a return on equity of 125.45%. The business had revenue of $84.75 billion for the quarter, compared to the consensus estimate of $84.31 billion. During the same period last year, the firm posted $4.00 earnings per share. Cencora’s quarterly revenue was up 5.1% on a year-over-year basis. Sell-side analysts predict that Cencora will post 17.87 EPS for the current fiscal year.

Insider Activity at Cencora

In other news, EVP Elizabeth Campbell sold 11,300 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $324.12, for a total value of $3,662,556.00. Following the completion of the sale, the executive vice president directly owned 19,455 shares in the company, valued at approximately $6,305,754.60. The trade was a 36.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.38% of the company’s stock.

Institutional Investors Weigh In On Cencora

A number of institutional investors have recently made changes to their positions in the business. Elevation Wealth Partners LLC grew its stake in shares of Cencora by 506.2% during the second quarter. Elevation Wealth Partners LLC now owns 97 shares of the company’s stock valued at $27,000 after buying an additional 81 shares during the last quarter. Bell Investment Advisors Inc bought a new stake in shares of Cencora in the 2nd quarter valued at about $28,000. Caitlin John LLC bought a new stake in shares of Cencora in the 2nd quarter valued at about $28,000. Cassaday & Co Wealth Management LLC purchased a new stake in Cencora during the 1st quarter valued at about $35,000. Finally, Downshift Financial LLC boosted its holdings in Cencora by 3,250.0% during the 3rd quarter. Downshift Financial LLC now owns 134 shares of the company’s stock valued at $40,000 after acquiring an additional 130 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Company Profile

(Get Free Report)

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical sourcing and distribution company. It provides branded, generic and specialty pharmaceuticals, over-the-counter products and related health care supplies to pharmacies, hospitals, health systems, physician practices and other health care providers.

The company also offers services to pharmaceutical and biotechnology manufacturers, including logistics, commercialization support, market access, consulting, clinical trial support and patient assistance programs.